

TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema

A.L. Bosma ¹, P.I. Spuls ¹, I. Garcia-Doval ^{2,3}, L. Naldi,⁴ D. Prieto-Merino,^{5,6} F. Tesch ⁷, C.J. Apfelbacher ⁸, B.W.M. Arents ⁹, S. Barbarot ¹⁰, E. Baselga,¹¹ M. Deleuran ¹², L.F. Eichenfield,¹³ L.A.A. Gerbens ¹, A.D. Irvine ^{14,15,16}, A. Manca,¹⁷ P. Mendes-Bastos ¹⁸, M.A. Middelkamp-Hup,¹ A. Roberts,¹⁹ J. Seneschal,²⁰ Å. Svensson,²¹ J.P. Thyssen,²² T. Torres,²³ F.M. Vermeulen,¹ C. Vestergaard,¹² L.B. von Kobyletzki,^{24,25} D. Wall,^{26,27} S. Weidinger,²⁸ J. Schmitt ^{7,29} and C. Flohr ³⁰

¹Amsterdam UMC, Location AMC, University of Amsterdam, Department of Dermatology, Amsterdam Public health, Infection and Immunity, Amsterdam, the Netherlands

²Research Unit, Academia Española de Dermatología y Venereología, Madrid, Spain

³Dermatology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain

⁴Centro Studi GISED, Bergamo, Italy

⁵Applied Statistics in Medical Research Group, Catholic University of Murcia (UCAM), Murcia, Spain

⁶Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, U.K.

⁷Center for Evidence-based Healthcare, Medizinische Fakultät Carl Gustav Carus, TU Dresden, Dresden, Germany

⁸Institute of Epidemiology and Preventive Medicine, University of Regensburg, Regensburg, Germany

⁹Dutch Association for People with Atopic Dermatitis, Nijkerk, the Netherlands

¹⁰Department of Dermatology, CHU Nantes, Nantes, France

¹¹Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

¹²Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark

¹³Department of Dermatology and Pediatrics, University of California, San Diego, CA, U.S.A.

¹⁴Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland

¹⁵National Children's Research Centre, Dublin, Ireland

¹⁶Department of Paediatric Dermatology, Our Lady's Children's Hospital, Dublin, Ireland

¹⁷Centre for Health Economics, University of York, York, U.K.

¹⁸Dermatology Centre, Hospital CUF Descobertas, Lisboa, Portugal

¹⁹Nottingham Support Group for Carers of Children with Eczema, Nottingham, U.K.

²⁰Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Diseases, University Hospital of Bordeaux, Bordeaux, France

²¹Department of Dermatology and Venereology, Skane University Hospital, Malmö, Sweden

²²Department of Dermatology and Allergy, Herlev-Gentofte Hospital, University of Copenhagen, Hellerup, Denmark

²³Department of Dermatology, Centro Hospitalar Universitário Porto, Porto, Portugal

²⁴Centre for Clinical Research, Lund University, Malmö, Sweden

²⁵Centre for Clinical Research, Örebro University, Örebro, Sweden

²⁶St James's Hospital, Dublin, Ireland

²⁷Irish Skin Foundation, Dublin, Ireland

²⁸Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany

²⁹University Allergy Center, University Hospital Carl Gustav Carus Dresden, Dresden, Germany

³⁰Unit for Population-Based Dermatology Research, St John's Institute of Dermatology, Guy's & St Thomas' NHS Foundation Trust and King's College London, London, U.K.

Summary

Correspondence

Carsten Flohr.

E-mail: carsten.flohr@kcl.ac.uk

Accepted for publication

15 August 2019

Background A long-term prospective observational safety study is essential to characterize fully the safety profile of systemic immunomodulating therapies for patients with atopic eczema. The TREatment of ATopic eczema (TREAT) Registry Taskforce offers a large platform to conduct such research using national registries that collect the same data using a predefined core dataset.

Funding sources

There was no specific funding for the development of this safety study protocol. TREATment of ATopic eczema (TREAT) NL (the Netherlands) and the UK–Irish Atopic eczema Systemic Therapy Registry (A-STAR) are funded by ZonMw and the British Skin Foundation, respectively. TREATgermany and the Danish TREAT registry are funded by Sanofi. The Spanish Biobadato registry is funded by both the Spanish Academy of Dermatology Foundation and Sanofi. The Italian AtopyReg registry is supported jointly by the Italian Society of Dermatology (SIDEmaST) and the Italian Association of Hospital Dermatologists. The Swedish and French TREAT registries are funded by departmental funds of several (university) hospitals. The Portuguese TREAT registry will be funded by the Portuguese Society of Dermatology.

Conflicts of interest

Full details available online in Appendix S1 (see Supporting Information)

B.W.M.A. and A.R. are contributing patients.

J.S. and C.F. contributed equally and share last authorship.

DOI 10.1111/bjd.18452

Objectives To present a protocol for a safety study comparing dupilumab with other systemic immunomodulating therapies in children and adults with moderate-to-severe atopic eczema, to assess the long-term safety risk of these therapies in a routine clinical care setting.

Methods We describe a registry-embedded international observational prospective cohort study. Adult and paediatric patients who start treatment with dupilumab or another systemic immunomodulating agent for their atopic eczema will be included. The primary end point is the incidence of malignancies (excluding nonmelanoma skin cancer) compared between the treatment groups. Secondary end points include other serious adverse events and adverse events of special interest, such as eye disorders and eosinophilia.

Conclusions This protocol delineates a safety study for dupilumab in adult and paediatric patients with atopic eczema, using a standardized methodological approach across several national registries. The protocol could also be used for other novel systemic immunomodulating therapies, and could provide licensing and reimbursement authorities, pharmaceutical companies and clinicians with safety evidence from a routine clinical care setting.

What's already known about this topic?

- There is a need for long-term data on the safety of systemic immunomodulating therapies in patients with atopic eczema.
- Regulatory bodies, such as the European Medicines Agency, increasingly stipulate the collection of such data as part of the licensing agreement for new treatments, to assess the new agent's long-term safety profile against established therapies.
- Large numbers of patients with a long duration of follow-up are necessary in order to detect rare events like malignancies.

What does this study add?

- The TREAT Registry Taskforce offers a platform to conduct such research with a network of multiple national atopic eczema research registries.
- We present a protocol for an investigator-initiated multicentre safety study comparing dupilumab with other systemic immunomodulating therapies in adults and subsequently adolescents and children with moderate-to-severe atopic eczema.
- This protocol can be used as a framework for similar studies for other novel systemic immunomodulating therapies across both adult and paediatric populations.

In a substantial number of patients with atopic eczema, systemic immunomodulating therapies are required because the disease is not sufficiently controlled with topical therapies.¹ Ciclosporin was, until recently, the only systemic treatment approved in Europe and only in adults with severe disease.² The frequency and duration of the use of ciclosporin is limited owing to the risk of renal toxicity and hypertension. In addition, neurological symptoms, fatigue or gastrointestinal symptoms, next to treatment failure are reasons for patients to discontinue their treatment.³ Ciclosporin has many potential contraindications and drug interactions. Alternative systemic immunomodulating therapies are used off-label and include methotrexate (MTX), mycophenolic acid (MA), mycophenolate mofetil (MMF) and azathioprine (AZA).⁴

These treatments are frequently prescribed for atopic eczema.^{5,6} MTX has limitations due to potential liver toxicity and teratogenicity.⁷ AZA and ciclosporin have been associated with an increased risk of incident cancer.^{8–11} However, the relative contribution of the diseases themselves and disease-related risk factors are difficult to separate from treatment-related factors.

Dupilumab, a monoclonal antibody binding to the alpha subunit of the interleukin 4 receptor (IL-4R α), has recently been approved by both the U.S. Food and Drug Administration and European Medicines Agency (EMA) for the treatment of adult patients with moderate-to-severe atopic eczema. Regarding short-time safety, clinical trials on dupilumab have shown no significant difference in the proportion of patients

with at least one adverse event (AE) in comparison to placebo, nor were there serious AEs (SAEs) related to dupilumab. Injection site reactions and conjunctivitis were the most commonly reported AEs.^{12,13} Eosinophilia has been reported in trials investigating dupilumab treatment in patients with asthma, with symptomatic hypereosinophilia being observed in rare cases.^{14,15} In atopic eczema studies, asymptomatic eosinophilia has been observed.^{12,16} In addition, conflicting evidence exists about the role of IL-4 in tumour promotion.^{17,18} The long-term safety of dupilumab has not yet been investigated.

In order to characterize fully the safety profile of the long-term use of dupilumab and mostly off-label systemic treatments in patients with atopic eczema, a long-term, prospective, observational safety study is essential and often stipulated by the licensing body, such as the EMA. Clinical registries can provide such data.

The TReatment of ATopic eczema (TREAT) Registry Taskforce is an international network of research registries that collect, in a harmonized fashion, the observational data of adult and paediatric patients with atopic eczema.¹⁹ Consensus was reached on a core dataset based on an international Delphi exercise among > 400 stakeholders from > 20 countries.^{20,21} Recently, recommendations for measurement instruments have been added to this core dataset.²² Currently, TREAT registries are being established in different European countries and in North America. Countries participating in the TREAT registry initiative are the U.K., Ireland, the U.S.A., Germany, the Netherlands, Denmark, Sweden, France, Italy, Spain and Portugal.

Data collected in a harmonized and standardized fashion across the TREAT registries can be used for the purpose of conducting a long-term safety study and here we present a study protocol for such an approach. The main objective of this study is to characterize the long-term safety profile of dupilumab compared with other systemic immunomodulating therapies for the treatment of atopic eczema in a routine clinical care setting.

Patients and methods

Study design

A registry-embedded long-term international prospective cohort study is conducted, aiming to recruit adult and paediatric patients with atopic eczema who start treatment with dupilumab and to compare the AE rates in this cohort with a cohort starting treatment with other systemic immunomodulating therapy (e.g. ciclosporin, MTX, MA, MMF and/or AZA). The study has an observational nature where interventions are initiated by the treating physician and not determined by the study. Coordinating centres of this study are the sites that coordinate the atopic eczema registries of the TREAT Registry Taskforce, each with a network of recruiting sites. Our European initiative has been registered as a research network with the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance.²³

Patient population

The study population consists of patients with a physician diagnosis of atopic eczema, who are starting on or switching to a systemic immunomodulating treatment for their atopic eczema that they have not received before. We aim to include as many patients treated with dupilumab as those treated with other systemic immunomodulating therapies as contemporaneous comparators. Participants need to be willing to comply with all study requirements and provide consent to participate in long-term follow-up for the collection of observational data during their visits, including AE recording and disease severity assessments. Written informed consent is obtained from each patient before participation.

Patients will not be allowed to be enrolled in the study if they are concurrently participating in an interventional study of systemic therapy for atopic eczema. The study participants can be enrolled in clinical trials prospectively. We will record if participants are participating in an investigational trial and include this as a variable in our analysis. If possible, follow-up visits for this safety study will be continued during the investigational trial. Participants can also be co-enrolled in other observational studies.

Study schedule

During the observation period, participants will be assessed on at least a 6-monthly basis while on therapy and at least annually off systemic immunomodulating treatment to collect data on AEs and reasons for potential changes in therapy. A ± 2 months visit window will be applied. The study aims to monitor patients for as long as possible, aiming for at least 5 years of follow-up for each participant.

Study end points

The primary end point of the study is the incidence rate ratio (IRR) of cancer [any pathology-confirmed malignant tumour or cancer, excluding nonmelanoma skin cancer (NMSC)] within the follow-up period comparing the group receiving dupilumab and the group receiving other systemic immunomodulating treatments.

The secondary end points are: (i) IRRs of SAEs [any untoward medical occurrence that results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, or consists of a congenital anomaly or birth defect, including serious infections (e.g. pneumonia, septicæmia, bone, joint and opportunistic infections)]²⁴ within the follow-up period comparing the groups; (ii) IRRs of other AEs of special interest in the groups [eosinophilia (an absolute eosinophil count $\geq 500/\mu\text{L}$), eye disorders (e.g. conjunctivitis, blepharitis and other eye disorders as diagnosed by an ophthalmologist, if appropriate), skin cancer (including both melanoma and NMSC), cardiac disorders (e.g. myocardial infarction), central nervous system disorders (e.g.

demyelination, peripheral neuropathy, seizures) and haematological disorders (e.g. aplastic anaemia, pancytopenia)]; and (iii) discontinuation rate of dupilumab due to AEs, compared with the discontinuation of the other systemic treatments.

Sample size

The definite power calculation will be based on the anticipated frequency of the outcomes. Under the assumption of 80% power and 5% alpha error (two-sided), a hazard ratio (HR) of 2 and 1 : 1 ratio of patients exposed vs. nonexposed to dupilumab (primary exposure) requires 66 events in the study.²⁵ Owing to nonrandom allocation of patients between the groups a R^2 of exposure to dupilumab explained by other covariates of 0.2 is considered. Assuming an annual incidence rate of any cancer (excluding NMSC) of 33 per 10 000 patients,²⁶ this results in 82 events.²⁷ There would be less power to detect the rare cancer specific subtypes, such as lymphoma and melanoma, unless the risk difference is very large. Our assumed HR for this power calculation is in line with the standard EMA requirements for a postmarketing safety study focused on cancer. A safety study should be large enough to detect a two-fold increase in risk for cancer (without NMSC). If the risk is higher than an HR of 2, the desired 82 cancer events would happen earlier in time; and if the risk is smaller than an HR of 2, a larger sample size would be required.

Furthermore, a dropout rate of 20%, including those with only limited exposition to dupilumab (exposure to dupilumab < 4 weeks) or other possible future biologicals, is assumed. To achieve these 82 events, we are dependent on the number of recruited patients, the speed of recruiting and the time the patients are under observation in the registry. Table 1 gives an overview of possible scenarios if recruitment is uniformly distributed over the recruitment period. By recruiting 1000 patients (N_y) per year over 3 years (Y_{rec}) the desired number of 82 events will appear in the ninth year of the study. By recruiting 800 patients per year over 4 years the desired number of 82 events will also appear in the ninth year of the study, but, overall, requires 3200 instead of 3000 patients to be included.

Exposure to dupilumab and other systemic immunomodulating treatments for atopic eczema will vary over time. It is expected that many patients will be exposed to more than one systemic immunomodulating agent within the study period. Differences in previous exposure to systemic immunomodulating atopic eczema treatments also have to be considered as potential confounders in the analysis. Additionally, a certain lag time has to be assumed between relevant exposures and the detection of incident cancer. Long latency adverse events, like cancer, will be linked to a drug if patients were ever exposed to the drug. Short latency adverse events, like eye disorders, will be linked to a drug if they took place while the patient was using the drug or within 90 days of the end of exposure.

Statistical analysis

The data from each participating registry will be analysed separately at first. A descriptive analysis of baseline patient characteristics and medical history will be presented. Categorical variables will be summarized by number and percentage in each category. Missing data will be displayed as a separate category where appropriate. Both cumulative incidence and incidence rates of malignancies, including 95% two-sided confidence intervals, will be estimated for the treatment groups.

The data from each registry will then be pooled and a comparative analysis performed on the pooled data to estimate if there is a difference in the incidence rates for malignancies or serious infections and the other AEs of interest between the treatment groups. In the primary confirmatory analysis exposure to dupilumab will be handled as a binary variable, i.e. patients are classified as exposed if they received dupilumab at least once within the study period; otherwise, they are classified as non-exposed. The log-rank test will be used followed by Cox proportional hazard models. Potential confounders and effect modifiers [age, sex, previous treatments (including previous phototherapy), malignancy history, smoking, family history, co-treatments, socioeconomic position, country, etc.] will be tested and included in the Cox model if they improve

Table 1 Distribution of follow-up time in years for different recruitment scenarios to achieve estimated event numbers at the end of the year, assuming recruitment is uniformly distributed over the recruitment period with 20% dropout and a background incidence of 33 per 10 000 person years

N_y	Y_{rec}	3 y	4 y	5 y	6 y	7 y	8 y	9 y	10 y	11 y	12 y	13 y	14 y
600	3	11	18	25	32	39	45	52	59	66	73	79	86
800	3	14	24	33	42	51	61	70	79	88	97	106	115
1000	3	18	29	41	53	64	76	87	99	110	121	132	143
600	4	11	19	28	38	47	56	65	74	83	92	101	110
800	4	14	25	38	50	62	75	87	99	111	123	135	147
1000	4	18	31	47	63	78	93	109	124	139	154	169	184
600	5	11	19	29	41	53	64	76	87	99	110	121	132
800	5	14	25	39	55	70	86	101	116	131	147	162	176
1000	5	18	31	49	69	88	107	126	145	164	183	202	221

N_y , number of recruited patients per year; Y_{rec} , duration of recruitment.

the model fit according to the Bayesian information criterion. The primary population for analysis will be all patients up to the point when 82 cancer events appear. The analyses will take into account switching from one drug to another, as well as medical (therapeutic) history, such that the person-years of follow-up switch to the new drug when this is initiated.

Sensitivity analyses will (i) consider history of malignancy; (ii) include analyses stratified by cancer type (including NMSC); (iii) consider lag time of exposure and cancer incidence of 12 months; and (iv) explore a potential dose-response effect of cumulative dupilumab exposure.

The same methods as described above will be applied to analyse secondary outcomes.

Data collection

Each country will use a purpose-built online data entry platform to collect the study data prospectively. All data will be pooled across countries for the final analyses. The pseudonymized data of each national registry will be hosted on secure servers. All data will be additionally stored on a back-up server in case of data loss. Only registered local investigators and delegated study members will have access to the data entry platform and only to the data of their own patients.

Data capture includes a case record form (CRF) based on the TREAT core dataset.^{21,22} A variety of parameters will be collected during the study visits. Concerning safety, data on the predefined AEs, including severity, seriousness and relatedness to therapy as part of pharmacovigilance will be recorded at each follow-up visit and entered into the CRF. All predefined malignancy and other predefined AE categories will be recorded using Medical Dictionary for Regulatory Activities (MedDRA) data dictionary coding. Where possible, the use of data from national cancer registries will be explored. In case of loss to follow-up, every effort will be made to collect information on the reason for this, including data on a potential (S)AE related to this.

Study governance structure

The safety study will be governed by a Steering Committee (SC), consisting of the Chair (Study Lead Investigator), the Co-Chair (Deputy Lead Investigator) and all country Principal Investigators (PIs) and co-PIs. The SC will be responsible for the running and management of the study and will meet regularly, at least every 6 months, either in person or via teleconference. In addition, there will be a Data Monitoring Committee (DMC), an independently formed committee with the responsibility of monitoring the patient safety. The DMC safeguards the interests of the patients participating in the study. It is the job of the DMC to monitor the comparative data and make recommendations to the SC on whether there are any ethical or safety reasons why the study should not be continued. They can also advise on modifications to the protocol. Apart from its Chair, the DMC will have at least one

statistician and at least two clinicians not directly involved in the study, with an interest in pharmacovigilance.

Discussion

The current evidence to inform clinical management for moderate-to-severe atopic eczema stems from a small body of randomized controlled trials.^{28–33} The psoriasis literature indicates that approximately 30% of patients entered into registries would be ineligible for clinical trials.³⁴ In addition, procedures differ between trials and routine clinical practice, which impairs the generalizability of the findings. There are no long-term, comparative and observational data on effectiveness and safety of systemic immunomodulating therapies for atopic eczema from a large-scale multicentre international cohort study. Several guidelines and a systematic review highlight these gaps.^{35–37}

The overall aim of the described study is to provide data on the long-term safety of dupilumab compared with other systemic immunomodulating therapies for the treatment of atopic eczema in adults and children. The observational nature of the study, using the platform of registries of the TREAT Registry Taskforce, guarantees the collection of data from patients in a routine clinical care setting. The described standardized methodological approach across registries will allow data pooling, in order to obtain the large number of patients required to acquire the power to detect rare events like malignancies.

A limitation of the study is that although the severity of disease requiring dupilumab treatment or another novel systemic agent is likely to be closely comparable with that of those exposed to another systemic immunomodulating drug intervention, the decision to start dupilumab treatment will most frequently be based on access to these novel systemic agents and a lack of suitability of or responsiveness to other immunomodulating therapies rather than on disease severity. This is likely to result in differences between treatment groups, for example in the responsiveness to standard agents, which cannot be quantified other than by fully documenting previous systemic treatments for atopic eczema and then adjust for such confounders in statistical analysis.

Individuals commencing novel systemic treatments have often received multiple systemic therapies in the past. Limiting the study only to new users of such therapies would restrict the dupilumab group to patients with contraindications for many other therapies. This approach would undermine the scope of evidence from the routine clinical care setting and introduce bias.³⁸ Our data will take into account sequential treatment switching decisions that typically take place in routine clinical practice and that are almost impossible to study in clinical trials.

The need for long-term safety studies for other therapies will increase, as many other novel therapies are currently being assessed in clinical trials. The described study protocol primarily concerns a comparison between dupilumab and other systemic therapies. However, this protocol can be used as a framework for similar studies for other novel systemic

immunomodulating therapies across both adult and paediatric populations within the TREAT Registry Taskforce. The described study could be adapted to include and collect information on any drug and AE of interest. While the presented protocol is focused on dupilumab, we will also collect similar AE data on all other systemic therapies the participants are on. This will allow safety comparisons between all other systemic immunomodulating therapies, provided that the number of treated patients and power is adequate.

This study will run as an investigator-led project but is open to receive financial support from charities, governments and pharmaceutical companies, who might want to task the study team with the follow-up of patients on their agents. This approach could provide pharmaceutical companies postauthorization safety data on their systemic therapies, as requested by licensing and regulatory bodies.

Next to the countries that have already started, several other countries have shown their interest in joining in the TREAT Registry Taskforce (<https://treat-registry-taskforce.org>) and establishing a TREAT registry. This offers opportunities for expansion of this and similar studies for other systemic therapies in the future.

References

- Weidinger S, Novak N. Atopic dermatitis. *Lancet* 2016; **387**:1109–22.
- European Medicines Agency. Questions and answers on Sandimmun, Sandimmun Neoral and associated names (ciclosporin, 10, 25, 50 and 100 mg capsules, 100 mg/ml oral solution and 50 mg/ml concentrate for solution for infusion). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Sandimmun_30/WC500144897.pdf (last accessed 20 July 2018).
- Garritsen FM, Roekevisch E, van der Schaft J *et al.* Ten years experience with oral immunosuppressive treatment in adult patients with atopic dermatitis in two academic centres. *J Eur Acad Dermatol Venereol* 2015; **29**:1905–12.
- Schmitt J, Schakel K, Schmitt N, Meurer M. Systemic treatment of severe atopic eczema: a systematic review. *Acta Derm Venereol* 2007; **87**:100–11.
- Proudfoot LE, Powell AM, Ayis S *et al.* The European TREATment of severe Atopic eczema in children Taskforce (TREAT) survey. *Br J Dermatol* 2013; **169**:901–9.
- Taylor K, Swan DJ, Affleck A *et al.* Treatment of moderate-to-severe atopic eczema in adults within the U.K.: results of a national survey of dermatologists. *Br J Dermatol* 2017; **176**:1617–23.
- Zachariae H, Kragballe K, Sogaard H. Methotrexate induced liver cirrhosis. Studies including serial liver biopsies during continued treatment. *Br J Dermatol* 1980; **102**:407–12.
- Pasternak B, Svanstrom H, Schmiegelow K *et al.* Use of azathioprine and the risk of cancer in inflammatory bowel disease. *Am J Epidemiol* 2013; **177**:1296–305.
- Cockburn IT, Krupp P. The risk of neoplasms in patients treated with cyclosporine A. *J Autoimmun* 1989; **2**:723–31.
- Mortimer PS, Thompson JF, Dawber RP *et al.* Hypertrichosis and multiple cutaneous squamous cell carcinomas in association with cyclosporin A therapy. *J R Soc Med* 1983; **76**:786–7.
- Price ML, Tidman MJ, Ogg CS, MacDonald DM. Skin cancer and cyclosporine therapy. *N Engl J Med* 1985; **313**:1420.
- Simpson EL, Bieber T, Guttman-Yassky E *et al.* Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. *N Engl J Med* 2016; **375**:2335–48.
- Blauvelt A, de Bruin-Weller M, Gooderham M *et al.* Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. *Lancet* 2017; **389**:2287–303.
- Castro M, Corren J, Pavord ID *et al.* Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. *N Engl J Med* 2018; **378**:2486–96.
- Wenzel S, Castro M, Corren J *et al.* Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. *Lancet* 2016; **388**:31–44.
- Faiz S, Giovannelli J, Podevin C *et al.* Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. *J Am Acad Dermatol* 2019; **81**:143–51.
- Hallett MA, Venmar KT, Fingleton B. Cytokine stimulation of epithelial cancer cells: the similar and divergent functions of IL-4 and IL-13. *Cancer Res* 2012; **72**:6338–43.
- Li Z, Chen L, Qin Z. Paradoxical roles of IL-4 in tumor immunity. *Cell Mol Immunol* 2009; **6**:415–22.
- Spuls PI, Gerbens LAA, Apfelbacher CJ *et al.* The International TREATment of ATopic Eczema (TREAT) Registry Taskforce: an initiative to harmonize data collection across national atopic eczema photo- and systemic therapy registries. *J Invest Dermatol* 2017; **137**:2014–16.
- Gerbens LA, Boyce AE, Wall D *et al.* TREATment of ATopic eczema (TREAT) Registry Taskforce: protocol for an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema registries. *Trials* 2017; **18**:87.
- Gerbens LAA, Apfelbacher CJ, Irvine AD *et al.* TREATment of ATopic eczema (TREAT) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo- and systemic therapy registries. *Br J Dermatol* 2019; **180**:790–801.
- Vermeulen FM, Gerbens LAA, Bosma AL *et al.* TREATment of ATopic eczema (TREAT) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registries. *Br J Dermatol* 2019; **181**:492–504.
- European Network of Centres for Pharmacovigilance and Pharmacovigilance. Network Detail: European TREATment of ATopic eczema Registry Taskforce. Available at: <http://www.encepp.eu/en/cepp/viewResource.htm?id=26053> (last accessed 17 June 2019).
- International conference of harmonization. Harmonised tripartite guideline. Clinical safety data management: definitions and standards for expedited reporting E2A. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use_en-15.pdf (last accessed 1 October 2019).
- Schoenfeld DA. Sample-size formula for the proportional-hazards regression model. *Biometrics* 1983; **39**:499–503.
- Arana A, Wentworth CE, Fernandez-Vidaurre C *et al.* Incidence of cancer in the general population and in patients with or without atopic dermatitis in the U.K. *Br J Dermatol* 2010; **163**:1036–43.
- Latouche A, Porcher R, Chevret S. Sample size formula for proportional hazards modelling of competing risks. *Stat Med* 2004; **23**:3263–74.
- Harper JI, Ahmed I, Barclay G *et al.* Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. *Br J Dermatol* 2000; **142**:52–8.

- 29 El-Khalawany MA, Hassan H, Shaaban D *et al.* Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt. *Eur J Pediatr* 2013; **172**:351–6.
- 30 Murphy LA, Atherton D. A retrospective evaluation of azathioprine in severe childhood atopic eczema, using thiopurine methyltransferase levels to exclude patients at high risk of myelosuppression. *Br J Dermatol* 2002; **147**:308–15.
- 31 Hon KL, Ching GK, Leung TF *et al.* Efficacy and tolerability at 3 and 6 months following use of azathioprine for recalcitrant atopic dermatitis in children and young adults. *J Dermatolog Treat* 2009; **20**:141–5.
- 32 Waxweiler WT, Agans R, Morrell DS. Systemic treatment of pediatric atopic dermatitis with azathioprine and mycophenolate mofetil. *Pediatr Dermatol* 2011; **28**:689–94.
- 33 Caufield M, Tom WL. Oral azathioprine for recalcitrant pediatric atopic dermatitis: clinical response and thiopurine monitoring. *J Am Acad Dermatol* 2013; **68**:29–35.
- 34 Garcia-Doval I, Carretero G, Vanaclocha F *et al.* Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. *Arch Dermatol* 2012; **148**:463–70.
- 35 Ring J, Alomar A, Bieber T *et al.* Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. *J Eur Acad Dermatol Venereol* 2012; **26**:1176–93.
- 36 Sidbury R, Davis DM, Cohen DE *et al.* Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. *J Am Acad Dermatol* 2014; **71**:327–49.
- 37 Roekevisch E, Spuls PI, Kuester D *et al.* Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. *J Allergy Clin Immunol* 2014; **133**:429–38.
- 38 Vandenbroucke J, Pearce N. Point: incident exposures, prevalent exposures, and causal inference: does limiting studies to persons who are followed from first exposure onward damage epidemiology? *Am J Epidemiol* 2015; **182**:826–33.

Supporting Information

Additional Supporting Information may be found in the online version of this article at the publisher's website:

Appendix S1. Conflicts of interest.

Appendix S1

Conflicts of interest

A.D.I. is a consultant to AbbVie, Sanofi-Genzyme, Regeneron and Novartis, and a Principal Investigator for AbbVie and Regeneron. A.M. is co-investigator on the UK–Irish Atopic eczema Systemic Therapy Registry (A-STAR) and a member of the Technology Appraisal Committee of the National Institute for Health and Care Excellence for England and Wales. C.J.A. has received consultancy fees from Dr. Wolff GmbH and Sanofi Genzyme, and institutional funding from Dr. Wolff GmbH. C.F. is Chief Investigator of A-STAR and his department has received funding from Sanofi for investigator-led microbiome research. C.V. has advised and given lectures for AbbVie, GlaxoSmithKline, LEO Pharma, Novartis and Sanofi-Genzyme, and has been involved in the development of PO-SCORAD. D.W. has acted in a consultancy capacity for Janssen & Novartis. E.B. has been a speaker for Sanofi, Almirall, Pierre-Fabre Dermatology; an investigator for Pfizer, AbbVie and Pierre-Fabre; and an advisor for Sanofi-Genzyme and Pierre-Fabre Dermatology. F.M.V. has been involved as a subinvestigator in clinical trials for AbbVie, Novartis, LEO Pharma, Lilly and Regeneron. I.G.-D. has received institutional funding from Sanofi. J. Schmitt has received institutional funding for investigator-initiated research from ALK, Novartis, Pfizer and Sanofi, and is co-principal investigator of the German atopic eczema registry (TREATgermany). J. Seneschal has received and has been speaker for Sanofi and Pierre Fabre dermatology. J.P.T. has been a speaker for Sanofi-Genzyme and LEO Pharma, an investigator for Sanofi-Genzyme, Eli Lilly & Co., AbbVie and LEO Pharma, and an advisor for Sanofi-Genzyme and Eli Lilly & Co. and Union Therapeutics. L.F.E. has served as a consultant to Allergan, Anacor/Pfizer, Dermavant, Dermira, DS Biopharma, Forte, Galderma Labs, Glenmark, Incyte, LEO Pharma, Lilly, Matrisys, Medimetriks/Otsuka, Menlo Therapeutics, Novan, Novartis, Ortho Dermatologics, Sanofi/Regeneron and TopMD, and has been an investigator for LEO Pharma and Sanofi/Regeneron. L.B.vK. is a consultant to Sanofi-Genzyme, and has received funding from Sanofi-Genzyme and LEO Pharma. L.N. has been a consultant for Lilly, Novartis and Sanofi. M.D. has been a speaker for Sanofi-Genzyme, Eli Lilly, Pierre Fabre and LEO Pharma, an investigator for Sanofi-Genzyme, Eli Lilly, AbbVie and LEO Pharma; and an advisor for Sanofi-Genzyme, Eli Lilly, Pierre Fabre, Meda, Galapagos, La Roche Posay, Pfeizer and Almirall. M.A.M.-H is an advisory board member for Sanofi-Genzyme. P.M.-B. has worked as a consultant/speaker for AbbVie, Pfizer, Janssen-Cilag, LEO Pharma, Novartis, Sanofi, Teva, L'Oreal, Cantabria Labs and Bayer, and has worked as investigator in

clinical trials promoted by AbbVie and Novartis. P.I.S. has served as a consultant to AbbVie, Anacor, LEO Pharma, Novartis and Sanofi, has received independent research grants from LEO Pharma and Schering-Plough, has been involved in the performance of clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of atopic eczema, and is Chief Investigator of the Dutch atopic eczema registry (TREAT NL). S.B. received research grants from Pierre Fabre Laboratory and Fondation pour la dermatite atopique; personal fees from Bioderma, Laboratoire La Roche Posay, Sanofi-Genzyme, AbbVie; and non-financial support from AbbVie, Novartis and Janssen. S.W. has received institutional research grants from Novartis, Pfizer and L'Oreal, has performed consultancies for Sanofi-Genzyme, Regeneron, LEO Pharma, Incyte and Novartis, has lectured at educational events sponsored by Sanofi-Genzyme, Regeneron, LEO Pharma, AbbVie and Galderma, is involved in the performance of clinical trials with many pharmaceutical industries that manufacture drugs used for, e.g., the treatment of psoriasis and atopic eczema and is co-principal investigator of the German atopic eczema registry (TREATgermany). T.T. has served as a consultant to AbbVie, LEO Pharma, Lilly, Novartis, Pfizer and Sanofi.